Serodus' Articles of Association March 2019
Serodus ASA (the “Company”) has successfully completed a directed share issue of NOK 27,4 million.
Serodus’ Board of Directors has, based on the issue authorization granted by the annual general meeting on 29 May 2018, issued new shares at a subscription price of NOK 1.30. The Company received NOK 27,4 million.
The proceeds of the Share Issue will be used for: 1) finalization of the ongoing regulatory required toxicological testing before long-term administration of SER150 in clinical trials, 2) production of clinical material and 3) preparation of the coming clinical trial in diabetic patients with kidney disease.